Just 1 week of full-dose ozanimod (Zeposia) was enough to bring symptom relief and biomarker improvement in patients with ulcerative colitis, a new analysis of placebo-controlled trial data indicated.

Ulcerative colitis (UC) is one of the most common inflammatory bowel diseases, a lifelong condition that can cause chronic inflammation and ulcers in the lining of the large intestine. This can lead ...

Massachusetts gastrointestinal disease firm, Cristcot, has announced results from its Phase III trial examining its hydrocortisone suppository and applicator for ulcerative colitis (UC), finding it to ...